(3-(hydroxymethyl)pyrrolidin-3-yl)methanol | 162687-17-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3-(hydroxymethyl)pyrrolidin-3-yl)methanol
• 英文别名: [3-(Hydroxymethyl)pyrrolidin-3-yl]methanol
• CAS: 162687-17-4
• 化学式: C₆H₁₃NO₂
• 分子量: 131.175
• InChiKey: JTZUKPJSXQMWEX-UHFFFAOYSA-N

物化性质

• 沸点：
  255.2±5.0 °C(Predicted)
• 密度：
  1.090±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3-(hydroxymethyl)pyrrolidin-3-yl)methanol 、 methyl 2-chloro-5-(1-cyclohexyl-1H-benzoimidazol-5-yl)-4-nitrothiophene-3-carboxylate 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 、 乙腈 为溶剂， 以76%的产率得到methyl 2-(3,3-bis(hydroxymethyl)pyrrolidin-1-yl)-5-(1-cyclohexyl-1H-benzoimidazol-5-yl)-4-nitrothiophene-3-carboxylate
  参考文献：
  名称：

  [EN] 3H-THIENO[3,4]PYRIMIDIN-4-ONEAND PYRROLOPYRIMID-4-ONE AS GRAM-POSITIVE ANTIBACTERIAL AGENTS
  [FR] 3H-THIÉNO[3,4]PYRIMIDIN-4-ONE ET PYRROLOPYRIMID-4-ONE UTILISÉES COMME AGENTS ANTIBACTÉRIENS CONTRE LES BACTÉRIES À GRAM POSITIF

  摘要：

  公开号：

  WO2015128334A9
• 作为产物：
  描述：

  dimethyl 1-benzylpyrrolidine-3,3-dicarboxylate 在 lithium aluminium tetrahydride 、 10 wt% Pd(OH)2 on carbon 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 0.25h， 生成 (3-(hydroxymethyl)pyrrolidin-3-yl)methanol
  参考文献：
  名称：

  [EN] 3H-THIENO[3,4]PYRIMIDIN-4-ONEAND PYRROLOPYRIMID-4-ONE AS GRAM-POSITIVE ANTIBACTERIAL AGENTS
  [FR] 3H-THIÉNO[3,4]PYRIMIDIN-4-ONE ET PYRROLOPYRIMID-4-ONE UTILISÉES COMME AGENTS ANTIBACTÉRIENS CONTRE LES BACTÉRIES À GRAM POSITIF

  摘要：

  公开号：

  WO2015128334A9

文献信息

• [EN] QUINOLONE ANTIBACTERIAL AGENTS<br/>[FR] AGENTS ANTIBACTERIENS A BASE DE QUINOLONE
  申请人：WARNER LAMBERT CO

  公开号：WO2005026165A1

  公开（公告）日：2005-03-24

  Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.

  公开了式I的化合物及其制备方法。进一步公开了制备式I生物活性化合物的方法，以及包括式I化合物的药用可接受组合物。本文公开的式I化合物可用于各种应用，包括用作抗菌剂。
• [EN] SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME<br/>[FR] COMPOSÉS 1,1'-BIPHÉNYLE SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARBUTUS BIOPHARMA INC

  公开号：WO2021158481A1

  公开（公告）日：2021-08-12

  The present invention includes substituted 1,1'-biphenyl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the invention can be used to treat, ameliorate, or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the invention can be used to treat, ameliorate, and/or prevent cancer in a patient.

  本发明包括取代的1,1'-联苯化合物，其类似物，以及包含它们的组合物。在一个方面，本发明中考虑的化合物可用于治疗、改善或预防患者体内的乙型肝炎病毒（HBV）和/或丙型肝炎病毒（HDV）感染。在另一个方面，本发明中考虑的化合物可用于治疗、改善和/或预防患者体内的癌症。
• [EN] PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE<br/>[FR] PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINES EN TANT QU'INHIBITEURS DE CDK ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：CANCER REC TECH LTD

  公开号：WO2015124941A1

  公开（公告）日：2015-08-27

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyrazolo[1,5-a]pyrimidine-5,7- diamine compounds (referred to herein as "PPDA compounds") that, inter alia, inhibit (e.g., selectively inhibit) CDK (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK; and to treat disorders including: disorders that are associated with CDK; disorders that result from an inappropriate activity of a cyclin-dependent kinase (CDK); disorders that are associated with CDK mutation; disorders that are associated with CDK overexpression; disorders that are associated with upstream pathway activation of CDK; disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; and cardiovascular disorders (including atherosclerosis). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些吡唑并[1,5-a]嘧啶-5,7-二胺化合物（以下简称为“PPDA化合物”），其在一定程度上抑制（例如，选择性抑制）CDK（例如CDK1、CDK2、CDK4、CDK5、CDK6、CDK7、CDK8、CDK9、CDK10、CDK11、CDK12、CDK13等）。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物和组合物，无论是体外还是体内，来抑制CDK；并用于治疗包括：与CDK相关的疾病；由于细胞周期依赖性激酶（CDK）不适当活性而导致的疾病；与CDK突变相关的疾病；与CDK过表达相关的疾病；与上游通路激活CDK相关的疾病；通过抑制CDK改善的疾病；增生性疾病；癌症；病毒感染（包括HIV）；神经退行性疾病（包括阿尔茨海默病和帕金森病）；缺血；肾脏疾病；和心血管疾病（包括动脉粥样硬化）等疾病。可选地，治疗还进一步包括与另一活性药剂（例如芳香化酶抑制剂、抗雌激素、Her2阻断剂、细胞毒性化疗药物等）一起进行治疗（例如同时或顺序治疗）。
• 8-METHOXYQUINOLONECARBOXYLIC ACID DERIVATIVE
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0677522A1

  公开（公告）日：1995-10-18

  An 8-methoxyquinolonecarboxylic acid derivative represented by general formula (I), and optical isomers, pharmaceutically acceptable salts and hydrates thereof, wherein R₁ represents hydrogen, lower alkyl, phenylalkyl or an in vivo hydrolyzable ester residue; R₂ represents hydrogen or methyl; and n represents an integer of 0 or 1. This derivative has a wide antimicrobial spectrum based on the activity potentiated in vitro and in vivo against gram-positive bacteria while retaining the potent antibacterial activity of the conventional quinolonecarboxylate bactericides against gram-negative bacteria. Since it scarcely has problematic side effects and is reduced in toxicity, it is promising as a bactericide having more excellent clinical effects.

  通式(I)代表的 8-甲氧基喹啉羧酸衍生物及其光学异构体、药学上可接受的盐和水合物，其中 R₁ 代表氢、低级烷基、苯基烷基或体内可水解的酯残基；R₂ 代表氢或甲基；n 代表 0 或 1 的整数。根据体外和体内对革兰氏阳性菌的增效活性，这种衍生物具有广泛的抗菌谱，同时保留了传统喹啉羧酸盐杀菌剂对革兰氏阴性菌的强效抗菌活性。由于它几乎没有副作用，毒性也较低，因此有望成为一种临床效果更佳的杀菌剂。
• 3H-thieno[3,4]pyrimidin-4-one and pyrrolopyrimidone as gram-positive antibacterial agents
  申请人：LABORATOIRE BIODIM

  公开号：EP2913333A1

  公开（公告）日：2015-09-02

  The invention relates to novel heteroaromatic derivatives of formula (I) and their addition salts thereof with acids and bases; their preparation, their use as drugs and pharmaceutical compositions and associations containing them. wherein A, B, T, V, X and Y represent organic substituents as defined herein, The compounds of formula (I) are able to inhibit the activity of the Gram-positive bacterial DltA enzyme and they are used to prevent and/or treat Gram-positive bacterial infections in humans or animals, alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity,

  本发明涉及式（I）的新型杂芳香族衍生物及其与酸和碱的加成盐；它们的制备、作为药物和药物组合物的用途以及含有它们的组合物。 其中 A、B、T、V、X 和 Y 代表本文定义的有机取代基、 式（I）化合物能够抑制革兰氏阳性菌 DltA 酶的活性，它们可单独或与抗菌剂、抗病毒剂或增强宿主先天免疫力的药物一起用于预防和/或治疗人或动物的革兰氏阳性菌感染、